Robert Tonks, MD
Interventional Cardiology · Twin Falls, IDNPI 1902197866
Payments from drug & device makers
What this record shows
Boston Scientific accounts for 81.1% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $2,864 and has fallen 98.7% since, to $37 in 2025. That places this record below the midpoint for interventional cardiology clinicians in ID, where the typical reported total is $3,406.
Across 41 payments — averaging $83.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Abbott$174
- AstraZeneca$116
- Abiomed$55
- E.r. Squibb & Sons, L.L.C.$52
- Novartis$48
- plus $200 from 9 others
What the payments were for
- Travel & lodging$2,00759%
- Food & beverage$1,39941%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 16 | $2,761 |
| Abbott | 3 | $174 |
| AstraZeneca | 1 | $116 |
| Abiomed | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 3 | $52 |
| Novartis | 3 | $48 |
| Pfizer | 3 | $38 |
| Akcea Therapeutics, Inc. | 1 | $32 |
| Johnson & Johnson | 2 | $27 |
| Bayer | 1 | $20 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
| United Therapeutics Corporation | 1 | $17 |
| Merck | 1 | $16 |
| Sanofi | 1 | $16 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,406 in reported general payments places this provider in the 50th percentile of 29 interventional cardiology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 194 | $169,727 |
| XareltoRivaroxaban | 63 | $60,002 |
| FarxigaDapagliflozin Propanediol | 14 | $12,120 |
| BrilintaTicagrelor | 14 | $11,902 |
| Repatha SureclickEvolocumab | 14 | $8,539 |
| Metoprolol Succinate | 467 | $4,355 |
| ClopidogrelClopidogrel Bisulfate | 257 | $2,941 |
| Rosuvastatin Calcium | 203 | $2,781 |
| Atorvastatin Calcium | 228 | $2,191 |
| Amiodarone Hcl | 118 | $1,553 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 32 | $1,518 |
| Ezetimibe | 67 | $1,304 |
| Amlodipine Besylate | 285 | $1,171 |
| Lisinopril | 187 | $1,149 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 158 | $1,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $38 | $169,727194 claims |
| Johnson & JohnsonXarelto | $27 | $60,00263 claims |
| AstraZenecaFarxiga, Brilinta | $116 | $24,02228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 29 interventional cardiology providers in Idaho.
Other interventional cardiology in Twin Falls
- Joseph HymasTwin Falls$3K
- Joseph WalshBoise$115K
- Kara DenbyBoise$18K
- Jeffrey HeslopBoise$17K
- Kendra CoonseBoise$17K
- Patrick ColemanBoise$11K
- Robert DuerrBoise$11K
- Andrew MichaelsNampa$7K
- George SamaanNampa$6K
- Ryley McPetersNampa$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.